Expert Analysis

Hepatitis and Opportunistic Coinfections

Source: CCO Independent Conference Coverage of the 2008 Conference on Retroviruses and Opportunistic Infections*

*CCO is an independent medical education company that provides state-of-the-art medical information to healthcare professionals through conference coverage and other educational programs.

Hepatitis and Opportunistic Coinfections

Faculty:
Richard E. Chaisson, MD Bruce Polsky, MD Jürgen K. Rockstroh, MD

CME CREDIT INFORMATION

Release Date: 03/21/08

Expiration Date: 03/20/09

Physicians: maximum of 1.5 AMA PRA Category 1 Credit(s)™

Pharmacists: 1.5 contact hours (0.15 CEUs)

Registered Nurses: 1.5 Nursing CE credits

Status: Please log in to view status

Learning Objectives

Upon completion of this activity, participants should be able to:

Summarize new data on the optimal timing of antiretroviral therapy in patients who present with acute opportunistic infections
Discuss the results of recent studies on the management of chronic hepatitis B and chronic hepatitis C in HIV-infected patients
Recount new findings on tuberculosis coinfection in HIV-infected patients
Describe recent insights regarding diverse clinical complications in HIV-infected patients, including Staphylococcus aureus and malignancies

Topics covered include:

Early vs Late HAART in Patients With Opportunistic Infections
Peginterferon alfa-2a Monotherapy in HIV/HCV-Coinfected Nonresponders to Peginterferon alfa-2a Plus Ribavirin
Decreased Liver-Related Morbidity and Mortality in HIV/HCV-Coinfected Patients Achieving SVR
HCV Recurrence Among HIV/HCV-Coinfected Homosexual Men Achieving Previous SVR
Model for End-Stage Liver Disease in HIV-Infected Liver Transplantation Candidates
Impact of Background NRTIs on Efficacy of Peginterferon Plus Ribavirin in HIV/HCV-Coinfected Patients
Further Insights Into Anti-HIV Activity of Entecavir
Extensively Drug-Resistant TB in South Africa
Management of Antiretroviral Therapy and IRIS in Patients Coinfected With TB
Chronic Trimethoprim/Sulfamethoxazole in HIV-Infected Patients Prevents S. Aureus Nasal Colonization
HIV-Related Cancers

Disclaimer: The materials published on the Clinical Care Options Web site reflect the views of the reviewers or authors of the CCO material, not those of Clinical Care Options, LLC, the CME provider, or the companies providing educational grants. The materials may discuss uses and dosages for therapeutic products that have not been approved by the United States Food and Drug Administration. A qualified healthcare professional should be consulted before using any therapeutic product discussed. Readers should verify all information and data before treating patients or using any therapies described in these materials.